Experimental Gene-Silencing Drug Produces Long-Duration Reduction in Lipoprotein(a), an Important Heart Disease Risk Factor
April 01, 2025
April 01, 2025
CLEVELAND, Ohio, April 1 -- The Cleveland Clinic issued the following news release on March 30, 2025:
* * *
Experimental Gene-Silencing Drug Produces Long-Duration Reduction in Lipoprotein(a), an Important Heart Disease Risk Factor
Single and double dosing showed significant reductions in the genetically inherited lipoprotein
CLEVELAND: Findings from a Phase 2 clinical trial reported by a Cleveland Clinic physician show a single dose of an expe . . .
* * *
Experimental Gene-Silencing Drug Produces Long-Duration Reduction in Lipoprotein(a), an Important Heart Disease Risk Factor
Single and double dosing showed significant reductions in the genetically inherited lipoprotein
CLEVELAND: Findings from a Phase 2 clinical trial reported by a Cleveland Clinic physician show a single dose of an expe . . .